Glenmark Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth
Glenmark Pharmaceuticals Ltd 路 Press Release 路 05 Nov 2026, 10:47 pm
Glenmark Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth Glenmark Pharmaceuticals reported Q2 FY27 consolidated revenue of Rs. 42,473 million, up ~20% YoY on a like-for-like basis. EBITDA reached Rs. 8,638 million (20.3% margin), with adjusted PAT at Rs. 4,852 million and reported PAT at Rs. 2,638 million. Regionally, India grew ~14% YoY like-for-like to Rs. 13,274 million, North America core business expanded ~31% YoY to Rs. 12,089 million, and Emerging Markets rose 33.2% YoY. Separately, Glenmark USA settled antitrust litigation with Humana for $15.28 million, fully provided for in the financials.
Original exchange filing (PDF)
More announcements from Glenmark Pharmaceuticals Ltd
- Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301 路 18 Nov 2026
- Glenmark Pharmaceuticals Inc., USA Launches Authorised Generic of INLYTA (axitinib) Tablets, 1 mg and 5mg 路 16 Nov 2026
- Schedule of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Initmation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst / Institutional Investor Meetings 路 10 Nov 2026
- Transcript of the Earnings Call 路 09 Nov 2026
- Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 路 06 Nov 2026
